New approaches to endocrine therapy for breast cancer

William J. Gradishar*

*Corresponding author for this work

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

The management of advanced hormone receptor–positive disease has evolved with the emergence of CDK4/6 inhibitors. Improvements in progression-free survival of approximately 10 months were noted in pivotal trials of palbociclib. Strong efficacy was also seen with ribociclib, which was recently approved by the FDA. In the adjuvant treatment setting of hormone receptor–positive disease, an important issue for consideration is the duration of endocrine therapy.

Original languageEnglish (US)
Pages (from-to)679-681
Number of pages3
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume15
Issue number5S
DOIs
StatePublished - May 2017

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'New approaches to endocrine therapy for breast cancer'. Together they form a unique fingerprint.

  • Cite this